# Phase 2b Study of ALTO-100 in MDD

> **NCT05712187** · PHASE2 · COMPLETED · sponsor: **Alto Neuroscience** · enrollment: 301 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** ALTO-100
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05712187
- **Lead sponsor:** Alto Neuroscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-10
- **Primary completion:** 2024-09-05
- **Final completion:** 2024-10-24
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05712187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05712187, "Phase 2b Study of ALTO-100 in MDD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05712187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*